A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors	Solid Tumor	Recruiting	Phase 1 / Phase 2	2025-01-23		NCT06016062

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
RemeGen Co., Ltd.	36

31 results · Page 1 of 2

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Anhui Provincial Hospital	Anhui	China	1
Beijing Tiantan Hospital, Capital Medical University	Beijing	China	8
Beijing University Cancer Hospital	Beijing	China	2
Chongqing University Cancer Hospital	Chongqing	China	17
Fujian Cancer Hospital	Fuzhou	China	37
Guangxi Medical University Cancer Hospital & Guangxi Cancer Institute	Nanning	China	2
Harbin Medical University Cancer Hospital	Harbin	China	35
Henan Cancer Hospital	Zhengzhou	China	60
Hunan Cancer Hospital	Changsha	China	47
Hunan Second People's Hospital	Changsha	China	1
Jilin Cancer Hospital	Changchun	China	15
Jinan Central Hospital	Jinan	China	15
Liaoning Cancer Hospital & Institute	Shenyang	China	11
Meizhou People's Hospital	Meizhou	China	6
Nanyang City Center Hospital	Nanyang	China	1
Nanyang Second General Hospital	Nanyang	China	2
Qilu Hospital of Shangdong University	Jinan	China	2
Shandong Cancer Hospital	Jinan	China	19
Shanghai Pulmonology Hospital	Shanghai	China	1
Shanxi Provincial Tumor Hospital	Taiyuan	China	1
Shengjing Hospital of China Medical University	Shenyang	China	23
Sichuan Cancer Hospital	Chengdu	China	21
Sun Yat-Sen University Cancer Center	Guangzhou	China	66
The Fifth Medical Center of Chinese PLA General Hospital	Beijing	China	3
The First Affiliated Hospital of Zhengzhou University	Zhengzhou	China	61

Clinical trials